Study to compare the efficacy and/or safety of masitinib at 3 mg/kg/day with switch to 4.5 then to 6 mg/kg/day to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Masitinib
Fibroblast growth factor receptor 3 inhibitor|Platelet-derived growth factor receptor inhibitor|Stem cell growth factor receptor inhibitor
What it measured
Main measures
Annualised relapse rate defined as the number of confirmed relapse per year
Relapses
Other measures (1)
• Response assessment:
Who could take part
Relapsing MS
Inclusion: 1. Patient with documented relapsing-remitting multiple sclerosis (RR-MS) according to revised McDonald’s criteria including MRI scan revealing lesion consistent with the diagnosis of MS. Exclusion: 1. Patients with primary progressive, secondary progressive or progressive relapsing multiple sclerosis.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The objective of the study is to compare the efficacy and/or safety of masitinib at 3 mg/kg/day with switch to 4.5 then to 6 mg/kg/day to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments
Loading reviews and guidelines…
Related trials
- Imatinib MS
Phase 2 · Status unknown
No result found
- Imatinib MS
Phase 2 · Stopped early
- RECYCLINE
Phase 2 · Stopped early
Stopped early
History
Started
Apr 2015
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error